We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Test Developed for Sleeping Sickness

By LabMedica International staff writers
Posted on 05 Jun 2012
Proteins imitating typical parts of the sleeping sickness parasite can be used in more efficient diagnostic tests, without the need for culturing dangerous parasites. More...


In the regions where Trypanosoma brucei gambiense, the causative agent of sleeping sickness is found, medical workers for decades already use a rapid diagnostic test, to screen millions of people each year on the presence of antibodies in their blood.

A scientist at the Antwerp Institute of Tropical Medicine (Belgium) has developed a new and better test by trying to synthesize artificial targets. These 'mimotopes' mimic only a part of the original target protein, but still are sufficient to react with the patient's antibodies. The investigator produced mimotopes that are reliable and react with infected patients' serum. These mimotopes now can be the base for a new generation of rapid diagnostic tests for sleeping sickness.

In the original tests the antibodies are demonstrated by presenting them targets they will also recognize and attack on real trypanosomes such as the variable surface glycoprotein that cover the parasite as a mantle. When antibody and target react, the test is positive and is made visible by for instance a color change or a clotting. Today those targets are obtained from living parasites that are raised in laboratory animals, and are a constant danger for the laboratory technicians.

In an early stage, the disease is easy to treat, but once the brain is invaded, the treatment becomes more complex and physicians must use medicines with dangerous, even deadly, side effects. Therefore, it is important to detect the infection early. Patients become disoriented, their sleeping pattern disintegrates, and they get motor and mental problems. This inevitably leads to coma and death. According to the World Health Organization (WHO; Geneva, Switzerland) estimates, sleeping sickness claims 10,000 to 20,000 lives each year. In recent years, the number of cases has come down substantially, thanks to campaigns against the disease, so error margins that were acceptable in the old days, because the tests still saved so many lives, now become inadmissible.

Related Links:

Antwerp Institute of Tropical Medicine
World Health Organization



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.